

European Psoriasis Guidelines

Therapy	Conventional systemic agents				small	tnf inhibitors				anti-	anti-IL17			anti-IL23			Symbols	Implications	
	Acitretin	Ciclosporin	Fumarates	Methotrexate	Apremilas t	Etanerce pt	Infliximab	Adalimum ab	Certolizu mab	Ustekinu mab	Secukinu mab	Ixekizuma b	Brodalum ab	Guselkum ab	Tildrakizu mab	Risankizu mab			
Concomitant psoriatic arthritis				↑↑ peripheral active joint involvement		↑↑ if non-responder to MTX							↑↑ if nonrespo nder to MTX		↑↑ if nonrespo nder to MTX				
Chronic inflammatory bowel disease: Crohn's Disease	↑ especially cases with mild paradoxical psoriasis			↑ 2nd choice oral treatment		↑↑ 1st choice						↓		↑ 2nd choice if anti-TNF alpha not suitable			↑↑	We believe that all or almost all informed people would make that choice.	
Chronic inflammatory bowel disease: Ulcerative colitis	↑ especially cases with mild paradoxical psoriasis	↑ 2nd choice oral treatment			↑ 2nd choice oral treatment		↑↑ 1st choice			↑↑ 1st choice			↓		↑ 2nd choice if anti-TNF alpha not suitable		↑	We believe that most informed people would make that choice, but a substantial number would not.	
Diabetes mel/ metabolic syndrome		↓		↓														See background text and specific recommendations	
Dyslipidaemia	↓																	↓	We believe that most informed people would make a choice against that intervention, but a substantial number would not.
Advanced heart failure	↑	↓		↑	↑	↓↓							↑					↓↓	We believe that all or almost all informed people would make a choice against that choice.
Heart Disease: Ischemic heart disease		↓		↑					↑										
Concomitant latent / treated TB	↑		↑		↑	↓↓							↑						
Pregnancy	↓↓	↑ preferred conventional	↓	↓↓	↓				↑ preferred choice biologic										